Quest Diagnostics (DGX) Cash from Financing Activities (2009 - 2026)

Quest Diagnostics has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$229.0 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 21.84% year-over-year to -$229.0 million; the TTM figure through Jun 2026 stood at -$915.0 million (down 222.65% YoY), while the FY2025 annual figure was -$1.4 billion, down 228.04% from the prior year.
• Cash from Financing Activities came in at -$229.0 million for Q2 2026 at Quest Diagnostics, down from -$152.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.8 billion in Q3 2024 to a low of -$561.0 million in Q1 2025.
• Average Cash from Financing Activities over 5 years is -$125.4 million, with a median of -$235.5 million recorded in 2022.
• Year-over-year, Cash from Financing Activities slumped 1147.37% in 2022 and soared 2232.53% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$545.0 million in 2022, then jumped by 123.85% to $130.0 million in 2023, then sank by 230.77% to -$170.0 million in 2024, then plunged by 68.82% to -$287.0 million in 2025, then climbed by 20.21% to -$229.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$229.0 million in Q2 2026, -$152.0 million in Q1 2026, and -$287.0 million in Q4 2025.